[go: up one dir, main page]

PL3215130T3 - Kompozycja farmaceutyczna zawierajęca bisoprolol i peryndopryl - Google Patents

Kompozycja farmaceutyczna zawierajęca bisoprolol i peryndopryl

Info

Publication number
PL3215130T3
PL3215130T3 PL15807949T PL15807949T PL3215130T3 PL 3215130 T3 PL3215130 T3 PL 3215130T3 PL 15807949 T PL15807949 T PL 15807949T PL 15807949 T PL15807949 T PL 15807949T PL 3215130 T3 PL3215130 T3 PL 3215130T3
Authority
PL
Poland
Prior art keywords
perindoril
bisoprolol
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
PL15807949T
Other languages
English (en)
Inventor
Gilles Fonknechten
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52345359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3215130(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of PL3215130T3 publication Critical patent/PL3215130T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL15807949T 2014-11-05 2015-11-04 Kompozycja farmaceutyczna zawierajęca bisoprolol i peryndopryl PL3215130T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1460654A FR3027803B1 (fr) 2014-11-05 2014-11-05 Composition pharmaceutique comprenant un betabloquant et un inhibiteur de l'enzyme de conversion
EP15807949.1A EP3215130B1 (fr) 2014-11-05 2015-11-04 Composition pharmaceutique comprenant le bisoprolol et le périndopril
PCT/FR2015/052975 WO2016071631A1 (fr) 2014-11-05 2015-11-04 Composition pharmaceutique comprenant le bisoprolol et le périndopril

Publications (1)

Publication Number Publication Date
PL3215130T3 true PL3215130T3 (pl) 2020-11-16

Family

ID=52345359

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15807949T PL3215130T3 (pl) 2014-11-05 2015-11-04 Kompozycja farmaceutyczna zawierajęca bisoprolol i peryndopryl

Country Status (24)

Country Link
EP (1) EP3215130B1 (pl)
CY (1) CY1123322T1 (pl)
DK (1) DK3215130T3 (pl)
EA (1) EA032808B1 (pl)
ES (1) ES2811904T3 (pl)
FR (1) FR3027803B1 (pl)
GE (1) GEP20196989B (pl)
HR (1) HRP20201518T1 (pl)
HU (1) HUE051947T2 (pl)
LT (1) LT3215130T (pl)
MA (1) MA40915B1 (pl)
MX (1) MX372717B (pl)
MY (1) MY187357A (pl)
PH (1) PH12017500786B1 (pl)
PL (1) PL3215130T3 (pl)
PT (1) PT3215130T (pl)
RS (1) RS60657B1 (pl)
RU (1) RU2702362C2 (pl)
SG (2) SG10201903656RA (pl)
SI (1) SI3215130T1 (pl)
TN (1) TN2017000170A1 (pl)
UA (1) UA122131C2 (pl)
WO (1) WO2016071631A1 (pl)
ZA (1) ZA201703078B (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR127403A1 (es) 2021-10-20 2024-01-17 Servier Lab Nuevas sales de trimetazidina
AU2024257489A1 (en) 2023-04-20 2025-10-30 Les Laboratoires Servier Novel trimetazidine solid phases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040137054A1 (en) 2002-05-03 2004-07-15 Alexandra Hager Stable pharmaceutical formulation for a combination of a statin and an ace-inhibitors
WO2010127205A2 (en) * 2009-04-30 2010-11-04 Dr. Reddy's Laboratories Ltd. Fixed dose drug combination formulations
WO2007010501A2 (en) * 2005-07-22 2007-01-25 Ranbaxy Laboratories Limited A pharmaceutical composition comprising a combination of beta blocker and an ace inhibitor
HU230877B1 (hu) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
EP2566472B1 (en) 2010-05-06 2015-01-07 Cal International Limited A pharmaceutical composition comprising aspirin and bisoprolol

Also Published As

Publication number Publication date
RU2017115341A3 (pl) 2019-05-21
TN2017000170A1 (fr) 2018-10-19
SG10201903656RA (en) 2019-05-30
SG11201703550SA (en) 2017-06-29
PH12017500786A1 (en) 2017-10-02
EA201790772A1 (ru) 2017-09-29
WO2016071631A1 (fr) 2016-05-12
HUE051947T2 (hu) 2021-03-29
RU2017115341A (ru) 2018-11-05
RS60657B1 (sr) 2020-09-30
EA032808B1 (ru) 2019-07-31
HRP20201518T1 (hr) 2020-12-11
LT3215130T (lt) 2020-08-25
MX2017005848A (es) 2017-06-27
SI3215130T1 (sl) 2020-11-30
FR3027803B1 (fr) 2018-02-09
MA40915B1 (fr) 2020-08-31
FR3027803A1 (fr) 2016-05-06
EP3215130A1 (fr) 2017-09-13
DK3215130T3 (da) 2020-09-21
EP3215130B1 (fr) 2020-07-08
PH12017500786B1 (en) 2023-10-11
CY1123322T1 (el) 2021-12-31
ES2811904T3 (es) 2021-03-15
PT3215130T (pt) 2020-08-26
MY187357A (en) 2021-09-22
ZA201703078B (en) 2020-11-25
UA122131C2 (uk) 2020-09-25
MX372717B (es) 2020-05-26
RU2702362C2 (ru) 2019-10-08
GEP20196989B (en) 2019-07-10

Similar Documents

Publication Publication Date Title
IL252532A0 (en) Polycyclic carbamoylpyridone compounds and their pharmaceutical use
IL254552A0 (en) Polycyclic carbamoylpyridone compounds and their pharmaceutical uses
GB201409471D0 (en) Pharmaceutical composition
IL252967B (en) Pharmaceutical preparations containing plasminogen and their uses
SG11201605366QA (en) Pharmaceutical composition containing pyridylaminoacetic acidcompound
PT3096740T (pt) Composição farmacêutica que compreende brinzolamida
GB201409488D0 (en) Pharmaceutical composition
GB201409485D0 (en) Pharmaceutical composition
ZA201703398B (en) Pharmaceutical composition and methods
ZA201703976B (en) Dihydropyrimidine-2-one compounds and medicinal uses thereof
ZA201508726B (en) Pharmaceutical composition
ZA201502073B (en) Pharmaceutical composition
GB201406172D0 (en) Therapy and pharmaceutical composition
GB201700560D0 (en) Pharmaceutical composition comprising docetaxel
PT3089740T (pt) Composição farmacêutica
ZA201703078B (en) Pharmaceutical composition comprising bisoprolol and perindoril
SG10201504332VA (en) Pharmaceutical Composition